LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: The Fall of Roe v. Wade : The Addiction Specialist's Role in Championing Reproductive Rights.

    Kurtz, Theresa / Smid, Marcela C

    Journal of addiction medicine

    2023  Volume 17, Issue 5, Page(s) 497–499

    Abstract: Reproductive age-pregnant individuals who use substances are disproportionately impacted by the US Supreme Court reversal of Roe v. Wade . Because of historic and ongoing discrimination against pregnant individuals who use substances, this group is at ... ...

    Abstract Reproductive age-pregnant individuals who use substances are disproportionately impacted by the US Supreme Court reversal of Roe v. Wade . Because of historic and ongoing discrimination against pregnant individuals who use substances, this group is at high risk for inadequate pregnancy options counseling and lack of access to safe and legal abortions. Fetal rights laws set a concerning precedent that further criminalize and penalize substance use in pregnancy. As addiction specialists, we have the professional responsibility to champion the reproductive freedoms of pregnant individuals who use substances. There are several ways that addiction specialists can uphold the reproductive rights of patients on an individual, state, and federal level, including the following: incorporate reproductive healthcare into addiction practices, help those seeking abortion navigate barriers, partner with perinatal healthcare clinicians to provide evidence-based addiction treatment during pregnancy, and support decriminalization and destigmatization of substance use, especially in pregnancy.
    MeSH term(s) Female ; Pregnancy ; Humans ; United States ; Supreme Court Decisions ; Reproductive Rights ; Abortion, Legal ; Substance-Related Disorders/therapy
    Language English
    Publishing date 2023-05-23
    Publishing country Netherlands
    Document type Journal Article
    ISSN 1935-3227
    ISSN (online) 1935-3227
    DOI 10.1097/ADM.0000000000001179
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Office-Based Management of Perinatal Substance Use and Substance Use Disorder for the General Obstetrician-Gynecologist.

    Kurtz, Theresa / Smid, Marcela C

    Obstetrics and gynecology clinics of North America

    2023  Volume 50, Issue 3, Page(s) 609–627

    Abstract: This is a review of substance use and substance use disorder in pregnancy, intended for the generalist obstetrician-gynecologist. Herein, the authors discuss legal considerations, outline definitions, review screening tools, introduce special ... ...

    Abstract This is a review of substance use and substance use disorder in pregnancy, intended for the generalist obstetrician-gynecologist. Herein, the authors discuss legal considerations, outline definitions, review screening tools, introduce special considerations and harm reduction, caution the use of urinary toxicology testing, and touch on the screening, brief intervention, and referral to treatment model. Furthermore, the authors provide a brief overview of the prevalence, maternal and neonatal risks, and treatment approaches for commonly used substances.
    MeSH term(s) Pregnancy ; Female ; Infant, Newborn ; Humans ; Gynecologists ; Obstetricians ; Substance-Related Disorders/diagnosis ; Substance-Related Disorders/therapy ; Referral and Consultation
    Language English
    Publishing date 2023-05-08
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1004315-9
    ISSN 1558-0474 ; 0889-8545
    ISSN (online) 1558-0474
    ISSN 0889-8545
    DOI 10.1016/j.ogc.2023.03.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Challenges in Perinatal Drug Testing.

    Kurtz, Theresa / Smid, Marcela C

    Obstetrics and gynecology

    2022  Volume 140, Issue 2, Page(s) 163–166

    MeSH term(s) Child ; Female ; Humans ; Infant, Newborn ; Infectious Disease Transmission, Vertical ; Parturition ; Perinatal Care ; Pregnancy ; Pregnancy Complications, Infectious
    Language English
    Publishing date 2022-07-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 207330-4
    ISSN 1873-233X ; 0029-7844
    ISSN (online) 1873-233X
    ISSN 0029-7844
    DOI 10.1097/AOG.0000000000004808
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Postpartum Extended-Release Buprenorphine Tissue Necrosis.

    Kurtz, Theresa / Charles, Jasmin E / Schwartz, Megan / Smid, Marcela C

    Obstetrics and gynecology

    2023  Volume 142, Issue 6, Page(s) 1504–1508

    Abstract: Background: Extended-release buprenorphine (XRB) may improve medication for opioid use disorder continuation among postpartum individuals. However, obstetric clinicians have relatively little experience with XRB. We describe two cases of XRB-related ... ...

    Abstract Background: Extended-release buprenorphine (XRB) may improve medication for opioid use disorder continuation among postpartum individuals. However, obstetric clinicians have relatively little experience with XRB. We describe two cases of XRB-related tissue necrosis in postpartum individuals to highlight recommended injection technique and management strategies for this rare complication.
    Cases: One patient developed tissue necrosis after her initial injection. Her wound was expectantly managed. Another patient on long-term XRB developed tissue necrosis within 1 day of injection. General surgery excised the depot. Both instances were attributed to injection of XRB intradermally rather than subcutaneously. Both patients continued monthly XRB without recurrence, suggesting that this complication is not an allergy.
    Conclusion: Clinicians should be able to prevent, recognize, and manage tissue necrosis, a rare complication of XRB injection.
    MeSH term(s) Humans ; Female ; Buprenorphine/therapeutic use ; Delayed-Action Preparations/adverse effects ; Opioid-Related Disorders/drug therapy ; Opiate Substitution Treatment ; Injections ; Analgesics, Opioid/therapeutic use ; Narcotic Antagonists
    Chemical Substances Buprenorphine (40D3SCR4GZ) ; Delayed-Action Preparations ; Analgesics, Opioid ; Narcotic Antagonists
    Language English
    Publishing date 2023-11-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 207330-4
    ISSN 1873-233X ; 0029-7844
    ISSN (online) 1873-233X
    ISSN 0029-7844
    DOI 10.1097/AOG.0000000000005425
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Mifepristone for miscarriage treatment in Utah: A survey of clinician knowledge and assessment of an educational video on future use.

    Kaiser, Jennifer E / Kurtz, Theresa / Glasser, Annabah / Brintz, Benjamin J / Gawron, Lori M / Turok, David K / Sanders, Jessica N

    AEM education and training

    2022  Volume 6, Issue 6, Page(s) e10834

    Abstract: Objectives: We aimed to: (a) describe current use of mifepristone for early pregnancy loss (EPL) management in Utah, (b) identify predictors of knowledge pre- and posteducational video, and (c) explore postvideo impacts on the likelihood to use ... ...

    Abstract Objectives: We aimed to: (a) describe current use of mifepristone for early pregnancy loss (EPL) management in Utah, (b) identify predictors of knowledge pre- and posteducational video, and (c) explore postvideo impacts on the likelihood to use mifepristone. Mifepristone is subject to the Food and Drug Administration's (FDA) Risk Evaluation and Mitigation Strategy (REMS) requirements.
    Methods: Between September 2020 and March 2021 we surveyed Utah clinicians from six specialties caring for people experiencing EPL, recruited through professional organizations and hospital listservs. Participants viewed a 3.5-minute educational video on mifepristone for EPL and completed pre- and postvideo questionnaires. We evaluated predictors of high prevideo and improved postvideo knowledge using random forest regression conditional importance measures and partial dependency plots. We described current mifepristone use and video effects on likelihood to use mifepristone.
    Results: Of 506 participants, most specialize in emergency medicine (172, 34%) and practice in private settings (253, 51%). Two-thirds had heard of mifepristone (328/471, 70%). Of 176/471 (37%) attempting provision of mifepristone, actual provision occurred for 59% (104/176). Baseline knowledge scores were low (mean 4.81/13 [37%] correct). Predictors of high prevideo knowledge include provision or attempted provision of mifepristone, having heard of mifepristone, providing EPL management expectantly or via medication, and specialty type. Mean postvideo knowledge scores improved by 3.27 points (68% improvement, paired t-test; 95% confidence interval 2.82-3.72, p < 0.0001). Postvideo, 66% (242/364) stated they are much more or somewhat more likely to use mifepristone, with compliance with FDA requirements cited as a barrier to utilization.
    Conclusions: Among Utah providers, baseline mifepristone knowledge and use for EPL management are low. An educational video improved knowledge and likelihood of use, but FDA REMS requirements continue to be a barrier to including mifepristone in medication management of EPL.
    Language English
    Publishing date 2022-12-20
    Publishing country United States
    Document type Journal Article
    ISSN 2472-5390
    ISSN (online) 2472-5390
    DOI 10.1002/aet2.10834
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top